The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global HCC (Hepatocellular Carcinoma) Biomarker Market Research Report 2025
Synopsis
Hepatocellular carcinoma (HCC) is the seventh most common cancer diagnosis worldwide with high associated mortality. HCC is a unique malignancy, as it typically arises in the setting of chronic liver disease in particular cirrhosis, with competing risks of liver failure, contributing to its low 5-year survival rates of 18%–20%. More than half of worldwide HCC-related deaths occur in Asia, due to endemic hepatitis B (HBV) infection. HCC incidence is rising in many Western countries due to the rising prevalence of nonalcoholic fatty liver disease, alcohol-related liver disease, and hepatitis C (HCV)-related complications despite the availability of direct acting antiviral therapies. The search for biomarkers in hepatocellular carcinoma continues despite recent approvals for immune checkpoint inhibitor combinations, tyrosine kinase inhibitors [TKIs], and antiangiogenesic agents. Biomarkers can be either predictive or prognostic and the only biomarker that has been used clinically is the prognostic biomarker α-fetoprotein (AFP).
The global HCC (Hepatocellular Carcinoma) Biomarker market was valued at US$ 842 million in 2023 and is anticipated to reach US$ 1279.7 million by 2030, witnessing a CAGR of 6.2% during the forecast period 2024-2030.
North American market for HCC (Hepatocellular Carcinoma) Biomarker is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for HCC (Hepatocellular Carcinoma) Biomarker is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for HCC (Hepatocellular Carcinoma) Biomarker in Hospitals is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of HCC (Hepatocellular Carcinoma) Biomarker include FUJIFILM, Eli Lilly and Company, Fujirebio, Roche Diagnostics, Fapon Biotech, Labcorp, Thermo Fisher Scientific, Abcam and Bio-Techne, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for HCC (Hepatocellular Carcinoma) Biomarker, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding HCC (Hepatocellular Carcinoma) Biomarker.
Report Scope
The HCC (Hepatocellular Carcinoma) Biomarker market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global HCC (Hepatocellular Carcinoma) Biomarker market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the HCC (Hepatocellular Carcinoma) Biomarker companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
FUJIFILM
Eli Lilly and Company
Fujirebio
Roche Diagnostics
Fapon Biotech
Labcorp
Thermo Fisher Scientific
Abcam
Bio-Techne
MyBiosource
RayBiotech
CUSABIO
Elabscience Biotechnology
Abbexa
Segment by Type
Alpha-fetoprotein (AFP)
Des-γ-carboxy Prothrombin (DCP)
Others
Segment by Application
Hospitals
Clinics
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of HCC (Hepatocellular Carcinoma) Biomarker companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Hepatocellular carcinoma (HCC) is the seventh most common cancer diagnosis worldwide with high associated mortality. HCC is a unique malignancy, as it typically arises in the setting of chronic liver disease in particular cirrhosis, with competing risks of liver failure, contributing to its low 5-year survival rates of 18%–20%. More than half of worldwide HCC-related deaths occur in Asia, due to endemic hepatitis B (HBV) infection. HCC incidence is rising in many Western countries due to the rising prevalence of nonalcoholic fatty liver disease, alcohol-related liver disease, and hepatitis C (HCV)-related complications despite the availability of direct acting antiviral therapies. The search for biomarkers in hepatocellular carcinoma continues despite recent approvals for immune checkpoint inhibitor combinations, tyrosine kinase inhibitors [TKIs], and antiangiogenesic agents. Biomarkers can be either predictive or prognostic and the only biomarker that has been used clinically is the prognostic biomarker α-fetoprotein (AFP).
The global HCC (Hepatocellular Carcinoma) Biomarker market was valued at US$ 842 million in 2023 and is anticipated to reach US$ 1279.7 million by 2030, witnessing a CAGR of 6.2% during the forecast period 2024-2030.
North American market for HCC (Hepatocellular Carcinoma) Biomarker is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for HCC (Hepatocellular Carcinoma) Biomarker is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for HCC (Hepatocellular Carcinoma) Biomarker in Hospitals is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of HCC (Hepatocellular Carcinoma) Biomarker include FUJIFILM, Eli Lilly and Company, Fujirebio, Roche Diagnostics, Fapon Biotech, Labcorp, Thermo Fisher Scientific, Abcam and Bio-Techne, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for HCC (Hepatocellular Carcinoma) Biomarker, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding HCC (Hepatocellular Carcinoma) Biomarker.
Report Scope
The HCC (Hepatocellular Carcinoma) Biomarker market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global HCC (Hepatocellular Carcinoma) Biomarker market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the HCC (Hepatocellular Carcinoma) Biomarker companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
FUJIFILM
Eli Lilly and Company
Fujirebio
Roche Diagnostics
Fapon Biotech
Labcorp
Thermo Fisher Scientific
Abcam
Bio-Techne
MyBiosource
RayBiotech
CUSABIO
Elabscience Biotechnology
Abbexa
Segment by Type
Alpha-fetoprotein (AFP)
Des-γ-carboxy Prothrombin (DCP)
Others
Segment by Application
Hospitals
Clinics
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of HCC (Hepatocellular Carcinoma) Biomarker companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global HCC (Hepatocellular Carcinoma) Biomarker Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Alpha-fetoprotein (AFP)
1.2.3 Des-γ-carboxy Prothrombin (DCP)
1.2.4 Others
1.3 Market by Application
1.3.1 Global HCC (Hepatocellular Carcinoma) Biomarker Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global HCC (Hepatocellular Carcinoma) Biomarker Market Perspective (2019-2030)
2.2 HCC (Hepatocellular Carcinoma) Biomarker Growth Trends by Region
2.2.1 Global HCC (Hepatocellular Carcinoma) Biomarker Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 HCC (Hepatocellular Carcinoma) Biomarker Historic Market Size by Region (2019-2024)
2.2.3 HCC (Hepatocellular Carcinoma) Biomarker Forecasted Market Size by Region (2025-2030)
2.3 HCC (Hepatocellular Carcinoma) Biomarker Market Dynamics
2.3.1 HCC (Hepatocellular Carcinoma) Biomarker Industry Trends
2.3.2 HCC (Hepatocellular Carcinoma) Biomarker Market Drivers
2.3.3 HCC (Hepatocellular Carcinoma) Biomarker Market Challenges
2.3.4 HCC (Hepatocellular Carcinoma) Biomarker Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top HCC (Hepatocellular Carcinoma) Biomarker Players by Revenue
3.1.1 Global Top HCC (Hepatocellular Carcinoma) Biomarker Players by Revenue (2019-2024)
3.1.2 Global HCC (Hepatocellular Carcinoma) Biomarker Revenue Market Share by Players (2019-2024)
3.2 Global HCC (Hepatocellular Carcinoma) Biomarker Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by HCC (Hepatocellular Carcinoma) Biomarker Revenue
3.4 Global HCC (Hepatocellular Carcinoma) Biomarker Market Concentration Ratio
3.4.1 Global HCC (Hepatocellular Carcinoma) Biomarker Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by HCC (Hepatocellular Carcinoma) Biomarker Revenue in 2023
3.5 HCC (Hepatocellular Carcinoma) Biomarker Key Players Head office and Area Served
3.6 Key Players HCC (Hepatocellular Carcinoma) Biomarker Product Solution and Service
3.7 Date of Enter into HCC (Hepatocellular Carcinoma) Biomarker Market
3.8 Mergers & Acquisitions, Expansion Plans
4 HCC (Hepatocellular Carcinoma) Biomarker Breakdown Data by Type
4.1 Global HCC (Hepatocellular Carcinoma) Biomarker Historic Market Size by Type (2019-2024)
4.2 Global HCC (Hepatocellular Carcinoma) Biomarker Forecasted Market Size by Type (2025-2030)
5 HCC (Hepatocellular Carcinoma) Biomarker Breakdown Data by Application
5.1 Global HCC (Hepatocellular Carcinoma) Biomarker Historic Market Size by Application (2019-2024)
5.2 Global HCC (Hepatocellular Carcinoma) Biomarker Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America HCC (Hepatocellular Carcinoma) Biomarker Market Size (2019-2030)
6.2 North America HCC (Hepatocellular Carcinoma) Biomarker Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America HCC (Hepatocellular Carcinoma) Biomarker Market Size by Country (2019-2024)
6.4 North America HCC (Hepatocellular Carcinoma) Biomarker Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe HCC (Hepatocellular Carcinoma) Biomarker Market Size (2019-2030)
7.2 Europe HCC (Hepatocellular Carcinoma) Biomarker Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe HCC (Hepatocellular Carcinoma) Biomarker Market Size by Country (2019-2024)
7.4 Europe HCC (Hepatocellular Carcinoma) Biomarker Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific HCC (Hepatocellular Carcinoma) Biomarker Market Size (2019-2030)
8.2 Asia-Pacific HCC (Hepatocellular Carcinoma) Biomarker Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific HCC (Hepatocellular Carcinoma) Biomarker Market Size by Region (2019-2024)
8.4 Asia-Pacific HCC (Hepatocellular Carcinoma) Biomarker Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America HCC (Hepatocellular Carcinoma) Biomarker Market Size (2019-2030)
9.2 Latin America HCC (Hepatocellular Carcinoma) Biomarker Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America HCC (Hepatocellular Carcinoma) Biomarker Market Size by Country (2019-2024)
9.4 Latin America HCC (Hepatocellular Carcinoma) Biomarker Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa HCC (Hepatocellular Carcinoma) Biomarker Market Size (2019-2030)
10.2 Middle East & Africa HCC (Hepatocellular Carcinoma) Biomarker Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa HCC (Hepatocellular Carcinoma) Biomarker Market Size by Country (2019-2024)
10.4 Middle East & Africa HCC (Hepatocellular Carcinoma) Biomarker Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 FUJIFILM
11.1.1 FUJIFILM Company Detail
11.1.2 FUJIFILM Business Overview
11.1.3 FUJIFILM HCC (Hepatocellular Carcinoma) Biomarker Introduction
11.1.4 FUJIFILM Revenue in HCC (Hepatocellular Carcinoma) Biomarker Business (2019-2024)
11.1.5 FUJIFILM Recent Development
11.2 Eli Lilly and Company
11.2.1 Eli Lilly and Company Company Detail
11.2.2 Eli Lilly and Company Business Overview
11.2.3 Eli Lilly and Company HCC (Hepatocellular Carcinoma) Biomarker Introduction
11.2.4 Eli Lilly and Company Revenue in HCC (Hepatocellular Carcinoma) Biomarker Business (2019-2024)
11.2.5 Eli Lilly and Company Recent Development
11.3 Fujirebio
11.3.1 Fujirebio Company Detail
11.3.2 Fujirebio Business Overview
11.3.3 Fujirebio HCC (Hepatocellular Carcinoma) Biomarker Introduction
11.3.4 Fujirebio Revenue in HCC (Hepatocellular Carcinoma) Biomarker Business (2019-2024)
11.3.5 Fujirebio Recent Development
11.4 Roche Diagnostics
11.4.1 Roche Diagnostics Company Detail
11.4.2 Roche Diagnostics Business Overview
11.4.3 Roche Diagnostics HCC (Hepatocellular Carcinoma) Biomarker Introduction
11.4.4 Roche Diagnostics Revenue in HCC (Hepatocellular Carcinoma) Biomarker Business (2019-2024)
11.4.5 Roche Diagnostics Recent Development
11.5 Fapon Biotech
11.5.1 Fapon Biotech Company Detail
11.5.2 Fapon Biotech Business Overview
11.5.3 Fapon Biotech HCC (Hepatocellular Carcinoma) Biomarker Introduction
11.5.4 Fapon Biotech Revenue in HCC (Hepatocellular Carcinoma) Biomarker Business (2019-2024)
11.5.5 Fapon Biotech Recent Development
11.6 Labcorp
11.6.1 Labcorp Company Detail
11.6.2 Labcorp Business Overview
11.6.3 Labcorp HCC (Hepatocellular Carcinoma) Biomarker Introduction
11.6.4 Labcorp Revenue in HCC (Hepatocellular Carcinoma) Biomarker Business (2019-2024)
11.6.5 Labcorp Recent Development
11.7 Thermo Fisher Scientific
11.7.1 Thermo Fisher Scientific Company Detail
11.7.2 Thermo Fisher Scientific Business Overview
11.7.3 Thermo Fisher Scientific HCC (Hepatocellular Carcinoma) Biomarker Introduction
11.7.4 Thermo Fisher Scientific Revenue in HCC (Hepatocellular Carcinoma) Biomarker Business (2019-2024)
11.7.5 Thermo Fisher Scientific Recent Development
11.8 Abcam
11.8.1 Abcam Company Detail
11.8.2 Abcam Business Overview
11.8.3 Abcam HCC (Hepatocellular Carcinoma) Biomarker Introduction
11.8.4 Abcam Revenue in HCC (Hepatocellular Carcinoma) Biomarker Business (2019-2024)
11.8.5 Abcam Recent Development
11.9 Bio-Techne
11.9.1 Bio-Techne Company Detail
11.9.2 Bio-Techne Business Overview
11.9.3 Bio-Techne HCC (Hepatocellular Carcinoma) Biomarker Introduction
11.9.4 Bio-Techne Revenue in HCC (Hepatocellular Carcinoma) Biomarker Business (2019-2024)
11.9.5 Bio-Techne Recent Development
11.10 MyBiosource
11.10.1 MyBiosource Company Detail
11.10.2 MyBiosource Business Overview
11.10.3 MyBiosource HCC (Hepatocellular Carcinoma) Biomarker Introduction
11.10.4 MyBiosource Revenue in HCC (Hepatocellular Carcinoma) Biomarker Business (2019-2024)
11.10.5 MyBiosource Recent Development
11.11 RayBiotech
11.11.1 RayBiotech Company Detail
11.11.2 RayBiotech Business Overview
11.11.3 RayBiotech HCC (Hepatocellular Carcinoma) Biomarker Introduction
11.11.4 RayBiotech Revenue in HCC (Hepatocellular Carcinoma) Biomarker Business (2019-2024)
11.11.5 RayBiotech Recent Development
11.12 CUSABIO
11.12.1 CUSABIO Company Detail
11.12.2 CUSABIO Business Overview
11.12.3 CUSABIO HCC (Hepatocellular Carcinoma) Biomarker Introduction
11.12.4 CUSABIO Revenue in HCC (Hepatocellular Carcinoma) Biomarker Business (2019-2024)
11.12.5 CUSABIO Recent Development
11.13 Elabscience Biotechnology
11.13.1 Elabscience Biotechnology Company Detail
11.13.2 Elabscience Biotechnology Business Overview
11.13.3 Elabscience Biotechnology HCC (Hepatocellular Carcinoma) Biomarker Introduction
11.13.4 Elabscience Biotechnology Revenue in HCC (Hepatocellular Carcinoma) Biomarker Business (2019-2024)
11.13.5 Elabscience Biotechnology Recent Development
11.14 Abbexa
11.14.1 Abbexa Company Detail
11.14.2 Abbexa Business Overview
11.14.3 Abbexa HCC (Hepatocellular Carcinoma) Biomarker Introduction
11.14.4 Abbexa Revenue in HCC (Hepatocellular Carcinoma) Biomarker Business (2019-2024)
11.14.5 Abbexa Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global HCC (Hepatocellular Carcinoma) Biomarker Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Alpha-fetoprotein (AFP)
Table 3. Key Players of Des-γ-carboxy Prothrombin (DCP)
Table 4. Key Players of Others
Table 5. Global HCC (Hepatocellular Carcinoma) Biomarker Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global HCC (Hepatocellular Carcinoma) Biomarker Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global HCC (Hepatocellular Carcinoma) Biomarker Market Size by Region (2019-2024) & (US$ Million)
Table 8. Global HCC (Hepatocellular Carcinoma) Biomarker Market Share by Region (2019-2024)
Table 9. Global HCC (Hepatocellular Carcinoma) Biomarker Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 10. Global HCC (Hepatocellular Carcinoma) Biomarker Market Share by Region (2025-2030)
Table 11. HCC (Hepatocellular Carcinoma) Biomarker Market Trends
Table 12. HCC (Hepatocellular Carcinoma) Biomarker Market Drivers
Table 13. HCC (Hepatocellular Carcinoma) Biomarker Market Challenges
Table 14. HCC (Hepatocellular Carcinoma) Biomarker Market Restraints
Table 15. Global HCC (Hepatocellular Carcinoma) Biomarker Revenue by Players (2019-2024) & (US$ Million)
Table 16. Global HCC (Hepatocellular Carcinoma) Biomarker Market Share by Players (2019-2024)
Table 17. Global Top HCC (Hepatocellular Carcinoma) Biomarker Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in HCC (Hepatocellular Carcinoma) Biomarker as of 2023)
Table 18. Ranking of Global Top HCC (Hepatocellular Carcinoma) Biomarker Companies by Revenue (US$ Million) in 2023
Table 19. Global 5 Largest Players Market Share by HCC (Hepatocellular Carcinoma) Biomarker Revenue (CR5 and HHI) & (2019-2024)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players HCC (Hepatocellular Carcinoma) Biomarker Product Solution and Service
Table 22. Date of Enter into HCC (Hepatocellular Carcinoma) Biomarker Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global HCC (Hepatocellular Carcinoma) Biomarker Market Size by Type (2019-2024) & (US$ Million)
Table 25. Global HCC (Hepatocellular Carcinoma) Biomarker Revenue Market Share by Type (2019-2024)
Table 26. Global HCC (Hepatocellular Carcinoma) Biomarker Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 27. Global HCC (Hepatocellular Carcinoma) Biomarker Revenue Market Share by Type (2025-2030)
Table 28. Global HCC (Hepatocellular Carcinoma) Biomarker Market Size by Application (2019-2024) & (US$ Million)
Table 29. Global HCC (Hepatocellular Carcinoma) Biomarker Revenue Market Share by Application (2019-2024)
Table 30. Global HCC (Hepatocellular Carcinoma) Biomarker Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 31. Global HCC (Hepatocellular Carcinoma) Biomarker Revenue Market Share by Application (2025-2030)
Table 32. North America HCC (Hepatocellular Carcinoma) Biomarker Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 33. North America HCC (Hepatocellular Carcinoma) Biomarker Market Size by Country (2019-2024) & (US$ Million)
Table 34. North America HCC (Hepatocellular Carcinoma) Biomarker Market Size by Country (2025-2030) & (US$ Million)
Table 35. Europe HCC (Hepatocellular Carcinoma) Biomarker Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 36. Europe HCC (Hepatocellular Carcinoma) Biomarker Market Size by Country (2019-2024) & (US$ Million)
Table 37. Europe HCC (Hepatocellular Carcinoma) Biomarker Market Size by Country (2025-2030) & (US$ Million)
Table 38. Asia-Pacific HCC (Hepatocellular Carcinoma) Biomarker Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 39. Asia-Pacific HCC (Hepatocellular Carcinoma) Biomarker Market Size by Region (2019-2024) & (US$ Million)
Table 40. Asia-Pacific HCC (Hepatocellular Carcinoma) Biomarker Market Size by Region (2025-2030) & (US$ Million)
Table 41. Latin America HCC (Hepatocellular Carcinoma) Biomarker Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 42. Latin America HCC (Hepatocellular Carcinoma) Biomarker Market Size by Country (2019-2024) & (US$ Million)
Table 43. Latin America HCC (Hepatocellular Carcinoma) Biomarker Market Size by Country (2025-2030) & (US$ Million)
Table 44. Middle East & Africa HCC (Hepatocellular Carcinoma) Biomarker Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 45. Middle East & Africa HCC (Hepatocellular Carcinoma) Biomarker Market Size by Country (2019-2024) & (US$ Million)
Table 46. Middle East & Africa HCC (Hepatocellular Carcinoma) Biomarker Market Size by Country (2025-2030) & (US$ Million)
Table 47. FUJIFILM Company Detail
Table 48. FUJIFILM Business Overview
Table 49. FUJIFILM HCC (Hepatocellular Carcinoma) Biomarker Product
Table 50. FUJIFILM Revenue in HCC (Hepatocellular Carcinoma) Biomarker Business (2019-2024) & (US$ Million)
Table 51. FUJIFILM Recent Development
Table 52. Eli Lilly and Company Company Detail
Table 53. Eli Lilly and Company Business Overview
Table 54. Eli Lilly and Company HCC (Hepatocellular Carcinoma) Biomarker Product
Table 55. Eli Lilly and Company Revenue in HCC (Hepatocellular Carcinoma) Biomarker Business (2019-2024) & (US$ Million)
Table 56. Eli Lilly and Company Recent Development
Table 57. Fujirebio Company Detail
Table 58. Fujirebio Business Overview
Table 59. Fujirebio HCC (Hepatocellular Carcinoma) Biomarker Product
Table 60. Fujirebio Revenue in HCC (Hepatocellular Carcinoma) Biomarker Business (2019-2024) & (US$ Million)
Table 61. Fujirebio Recent Development
Table 62. Roche Diagnostics Company Detail
Table 63. Roche Diagnostics Business Overview
Table 64. Roche Diagnostics HCC (Hepatocellular Carcinoma) Biomarker Product
Table 65. Roche Diagnostics Revenue in HCC (Hepatocellular Carcinoma) Biomarker Business (2019-2024) & (US$ Million)
Table 66. Roche Diagnostics Recent Development
Table 67. Fapon Biotech Company Detail
Table 68. Fapon Biotech Business Overview
Table 69. Fapon Biotech HCC (Hepatocellular Carcinoma) Biomarker Product
Table 70. Fapon Biotech Revenue in HCC (Hepatocellular Carcinoma) Biomarker Business (2019-2024) & (US$ Million)
Table 71. Fapon Biotech Recent Development
Table 72. Labcorp Company Detail
Table 73. Labcorp Business Overview
Table 74. Labcorp HCC (Hepatocellular Carcinoma) Biomarker Product
Table 75. Labcorp Revenue in HCC (Hepatocellular Carcinoma) Biomarker Business (2019-2024) & (US$ Million)
Table 76. Labcorp Recent Development
Table 77. Thermo Fisher Scientific Company Detail
Table 78. Thermo Fisher Scientific Business Overview
Table 79. Thermo Fisher Scientific HCC (Hepatocellular Carcinoma) Biomarker Product
Table 80. Thermo Fisher Scientific Revenue in HCC (Hepatocellular Carcinoma) Biomarker Business (2019-2024) & (US$ Million)
Table 81. Thermo Fisher Scientific Recent Development
Table 82. Abcam Company Detail
Table 83. Abcam Business Overview
Table 84. Abcam HCC (Hepatocellular Carcinoma) Biomarker Product
Table 85. Abcam Revenue in HCC (Hepatocellular Carcinoma) Biomarker Business (2019-2024) & (US$ Million)
Table 86. Abcam Recent Development
Table 87. Bio-Techne Company Detail
Table 88. Bio-Techne Business Overview
Table 89. Bio-Techne HCC (Hepatocellular Carcinoma) Biomarker Product
Table 90. Bio-Techne Revenue in HCC (Hepatocellular Carcinoma) Biomarker Business (2019-2024) & (US$ Million)
Table 91. Bio-Techne Recent Development
Table 92. MyBiosource Company Detail
Table 93. MyBiosource Business Overview
Table 94. MyBiosource HCC (Hepatocellular Carcinoma) Biomarker Product
Table 95. MyBiosource Revenue in HCC (Hepatocellular Carcinoma) Biomarker Business (2019-2024) & (US$ Million)
Table 96. MyBiosource Recent Development
Table 97. RayBiotech Company Detail
Table 98. RayBiotech Business Overview
Table 99. RayBiotech HCC (Hepatocellular Carcinoma) Biomarker Product
Table 100. RayBiotech Revenue in HCC (Hepatocellular Carcinoma) Biomarker Business (2019-2024) & (US$ Million)
Table 101. RayBiotech Recent Development
Table 102. CUSABIO Company Detail
Table 103. CUSABIO Business Overview
Table 104. CUSABIO HCC (Hepatocellular Carcinoma) Biomarker Product
Table 105. CUSABIO Revenue in HCC (Hepatocellular Carcinoma) Biomarker Business (2019-2024) & (US$ Million)
Table 106. CUSABIO Recent Development
Table 107. Elabscience Biotechnology Company Detail
Table 108. Elabscience Biotechnology Business Overview
Table 109. Elabscience Biotechnology HCC (Hepatocellular Carcinoma) Biomarker Product
Table 110. Elabscience Biotechnology Revenue in HCC (Hepatocellular Carcinoma) Biomarker Business (2019-2024) & (US$ Million)
Table 111. Elabscience Biotechnology Recent Development
Table 112. Abbexa Company Detail
Table 113. Abbexa Business Overview
Table 114. Abbexa HCC (Hepatocellular Carcinoma) Biomarker Product
Table 115. Abbexa Revenue in HCC (Hepatocellular Carcinoma) Biomarker Business (2019-2024) & (US$ Million)
Table 116. Abbexa Recent Development
Table 117. Research Programs/Design for This Report
Table 118. Key Data Information from Secondary Sources
Table 119. Key Data Information from Primary Sources
List of Figures
Figure 1. Global HCC (Hepatocellular Carcinoma) Biomarker Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global HCC (Hepatocellular Carcinoma) Biomarker Market Share by Type: 2023 VS 2030
Figure 3. Alpha-fetoprotein (AFP) Features
Figure 4. Des-γ-carboxy Prothrombin (DCP) Features
Figure 5. Others Features
Figure 6. Global HCC (Hepatocellular Carcinoma) Biomarker Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 7. Global HCC (Hepatocellular Carcinoma) Biomarker Market Share by Application: 2023 VS 2030
Figure 8. Hospitals Case Studies
Figure 9. Clinics Case Studies
Figure 10. Others Case Studies
Figure 11. HCC (Hepatocellular Carcinoma) Biomarker Report Years Considered
Figure 12. Global HCC (Hepatocellular Carcinoma) Biomarker Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 13. Global HCC (Hepatocellular Carcinoma) Biomarker Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 14. Global HCC (Hepatocellular Carcinoma) Biomarker Market Share by Region: 2023 VS 2030
Figure 15. Global HCC (Hepatocellular Carcinoma) Biomarker Market Share by Players in 2023
Figure 16. Global Top HCC (Hepatocellular Carcinoma) Biomarker Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in HCC (Hepatocellular Carcinoma) Biomarker as of 2023)
Figure 17. The Top 10 and 5 Players Market Share by HCC (Hepatocellular Carcinoma) Biomarker Revenue in 2023
Figure 18. North America HCC (Hepatocellular Carcinoma) Biomarker Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 19. North America HCC (Hepatocellular Carcinoma) Biomarker Market Share by Country (2019-2030)
Figure 20. United States HCC (Hepatocellular Carcinoma) Biomarker Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. Canada HCC (Hepatocellular Carcinoma) Biomarker Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Europe HCC (Hepatocellular Carcinoma) Biomarker Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Europe HCC (Hepatocellular Carcinoma) Biomarker Market Share by Country (2019-2030)
Figure 24. Germany HCC (Hepatocellular Carcinoma) Biomarker Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. France HCC (Hepatocellular Carcinoma) Biomarker Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. U.K. HCC (Hepatocellular Carcinoma) Biomarker Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Italy HCC (Hepatocellular Carcinoma) Biomarker Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Russia HCC (Hepatocellular Carcinoma) Biomarker Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Nordic Countries HCC (Hepatocellular Carcinoma) Biomarker Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Asia-Pacific HCC (Hepatocellular Carcinoma) Biomarker Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Asia-Pacific HCC (Hepatocellular Carcinoma) Biomarker Market Share by Region (2019-2030)
Figure 32. China HCC (Hepatocellular Carcinoma) Biomarker Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Japan HCC (Hepatocellular Carcinoma) Biomarker Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. South Korea HCC (Hepatocellular Carcinoma) Biomarker Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Southeast Asia HCC (Hepatocellular Carcinoma) Biomarker Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. India HCC (Hepatocellular Carcinoma) Biomarker Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Australia HCC (Hepatocellular Carcinoma) Biomarker Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Latin America HCC (Hepatocellular Carcinoma) Biomarker Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Latin America HCC (Hepatocellular Carcinoma) Biomarker Market Share by Country (2019-2030)
Figure 40. Mexico HCC (Hepatocellular Carcinoma) Biomarker Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Brazil HCC (Hepatocellular Carcinoma) Biomarker Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Middle East & Africa HCC (Hepatocellular Carcinoma) Biomarker Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Middle East & Africa HCC (Hepatocellular Carcinoma) Biomarker Market Share by Country (2019-2030)
Figure 44. Turkey HCC (Hepatocellular Carcinoma) Biomarker Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Saudi Arabia HCC (Hepatocellular Carcinoma) Biomarker Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. FUJIFILM Revenue Growth Rate in HCC (Hepatocellular Carcinoma) Biomarker Business (2019-2024)
Figure 47. Eli Lilly and Company Revenue Growth Rate in HCC (Hepatocellular Carcinoma) Biomarker Business (2019-2024)
Figure 48. Fujirebio Revenue Growth Rate in HCC (Hepatocellular Carcinoma) Biomarker Business (2019-2024)
Figure 49. Roche Diagnostics Revenue Growth Rate in HCC (Hepatocellular Carcinoma) Biomarker Business (2019-2024)
Figure 50. Fapon Biotech Revenue Growth Rate in HCC (Hepatocellular Carcinoma) Biomarker Business (2019-2024)
Figure 51. Labcorp Revenue Growth Rate in HCC (Hepatocellular Carcinoma) Biomarker Business (2019-2024)
Figure 52. Thermo Fisher Scientific Revenue Growth Rate in HCC (Hepatocellular Carcinoma) Biomarker Business (2019-2024)
Figure 53. Abcam Revenue Growth Rate in HCC (Hepatocellular Carcinoma) Biomarker Business (2019-2024)
Figure 54. Bio-Techne Revenue Growth Rate in HCC (Hepatocellular Carcinoma) Biomarker Business (2019-2024)
Figure 55. MyBiosource Revenue Growth Rate in HCC (Hepatocellular Carcinoma) Biomarker Business (2019-2024)
Figure 56. RayBiotech Revenue Growth Rate in HCC (Hepatocellular Carcinoma) Biomarker Business (2019-2024)
Figure 57. CUSABIO Revenue Growth Rate in HCC (Hepatocellular Carcinoma) Biomarker Business (2019-2024)
Figure 58. Elabscience Biotechnology Revenue Growth Rate in HCC (Hepatocellular Carcinoma) Biomarker Business (2019-2024)
Figure 59. Abbexa Revenue Growth Rate in HCC (Hepatocellular Carcinoma) Biomarker Business (2019-2024)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
